Clinical Scorecard: Ependymomas in the Posterior Fossa: An In-Depth Analysis of Molecular Classification, Treatment Protocols, and Clinical Outcomes (Part I on Ependymomas in Various Locations)

At a Glance

Key Highlights

• Ependymomas represent approximately 5% of pediatric CNS tumors, with two-thirds in the posterior fossa.
• Molecular profiling has shifted WHO classification from histologic to integrated molecular entities.
• PFA tumors are linked to poorer outcomes and specific genomic alterations like 1q gain and/or 6q loss.
• Surgical management, particularly gross total resection (GTR), significantly influences survival outcomes.
• MRI is essential for diagnosis, surgical planning, and monitoring of ependymomas.

Guideline-Based Recommendations

Diagnosis

• MRI is the primary modality for assessing posterior fossa ependymomas.

Management

• Surgical resection is the central management strategy, with GTR preferred for better outcomes.

Monitoring & Follow-up

• Craniospinal MRI is indicated at diagnosis, during surveillance, and upon recurrence.

Risks

• Recurrent or refractory disease develops in nearly 45% of affected children.

Patient & Prescribing Data

Children with posterior fossa ependymomas.

GTR followed by immediate conformal radiotherapy shows improved survival compared to subtotal resection (STR).

Clinical Best Practices

• Consider molecular subgroup classification for prognostic assessment and treatment planning.
• Evaluate the need for second-look surgery in patients with residual tumor when safe.

Related Resources & Content

• Source Article